Chapter 15. Targeting Measles Virus Entry

  1. David T. Curiel M.D. and
  2. Joanne T. Douglas Ph.D.
  1. Anthea L. Hammond Ph.D.,
  2. Richard K. Plemper Ph.D. and
  3. Roberto Cattaneo Ph.D.

Published Online: 31 MAR 2003

DOI: 10.1002/0471234303.ch15

Vector Targeting for Therapeutic Gene Delivery

Vector Targeting for Therapeutic Gene Delivery

How to Cite

Hammond, A. L., Plemper, R. K. and Cattaneo, R. (2002) Targeting Measles Virus Entry, in Vector Targeting for Therapeutic Gene Delivery (eds D. T. Curiel and J. T. Douglas), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/0471234303.ch15

Editor Information

  1. Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, The University of Alabama at Birmingham, USA

Author Information

  1. Molecular Medicine Program, Mayo Foundation, Rochester, Minnesota, USA

Publication History

  1. Published Online: 31 MAR 2003
  2. Published Print: 9 AUG 2002

ISBN Information

Print ISBN: 9780471434795

Online ISBN: 9780471234302



  • measles virus;
  • oncolytic therapy;
  • targeting;
  • cell attachment;
  • cell entry;
  • domain display;
  • single chain antibodies


Measles virus (MV) replicates preferentially in transformed cells. Its negative strand RNA genome does not integrate or recombine, and its pleomorphic envelope does not impose a rigid upper limit to the size of packaged genomes. To redirect cell entry, replicating MVs have been produced in which the standard attachment protein was replaced by one with an additional specificity domain. Specificity domains as diverse as a growth factor or a single chain antibody are able to confer entry through targeted receptors. MV mutants with reduced or ablated binding to the natural receptors are being produced, and may have applications in different oncolytic therapies.